cBrain appoints new CFO
Company Announcement no. 07/2025 cBrain appoints new CFO Copenhagen, June 11, 2025…
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
June 06, 2025 16:00 ET | Source: Zealand Pharma Company announcement –…
Quantum Metal Recovery Inc. Responds to Besra Gold’s ASX Announcement, Initiates Legal Proceedings in Ontario
PENANG, Malaysia, June 6, 2025 /PRNewswire/ -- Quantum Metal Recovery Inc. (QMRI),…
Olympism365 Summit day one: first concrete commitments made for a sustainable future through sport
04 June 2025 - The Olympism365 Summit: Sport for a Better World, hosted by…
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them
Company announcement no. 7/2025 In accordance with Article 19 (3) of the…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…